ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors
Shots:
- ABL Bio has signed a clinical trial collaboration and supply agreement with Merck for the development of ABL103 plus Keytruda to treat advanced or metastatic solid tumors
- As per the agreement, ABL Bio will carry out the P-Ib/II clinical evaluation for the safety & efficacy of ABL103 in addition to Keytruda, with Merck providing Keytruda for the same. The dose escalation part of its P-I study is underway across South Korea
- ABL103, developed using ABL Bio's Grabody-T platform, is a bispecific antibody that targets B7-H4 & 4-1BB. It activates 4-1BB signaling in tumor microenvironments with B7-H4 antigens, enabling T cells to selectively attack tumor cells without harming normal cells
Ref: PR Newswire | Image: ABL Bio & Merck
Related News:- Merck Reports the US FDA’s Approval of Keytruda Plus Pemetrexed and Platinum Chemotherapy to Treat Malignant Pleural Mesothelioma (MPM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
